Idiopathic Hypersomnia drug pipeline
2 compounds from 1 company are in active clinical development for idiopathic hypersomnia, including 1 at Phase 3 or beyond.
2Compounds
1Company
1Phase 3+
1Upcoming readout
1Trials recruiting
- Phase 3 1
- Phase 2 1
Mechanisms: Small molecule (2)
Pipeline data compiled July 2026 · every fact sourced.
Upcoming readouts & recent results
Vibrance-3 Phase 2 topline results anticipated in idiopathic hypersomnia (primary endpoint: change in Epworth Sleepiness Scale at Week 8). ↗
REVITALYZ Phase 3 positive topline: LUMRYZ met the primary ESS endpoint and all key secondary endpoints (PGI-C, IHSS, ESS worsening on placebo), each p<0.0001, in adults with idiopathic hypersomnia; sNDA planned by end of 2026. ↗
Compounds in development (2)
| Compound | Company | Phase | Status | Mechanism |
|---|---|---|---|---|
| LUMRYZ (sodium oxybate extended-release) | Alkermes plc | Phase 3 | Active | GABA-B receptor Agonist |
| AlixorextonOrphan | Alkermes plc | Phase 2 | Recruiting | OX2R Agonist |
Trials recruiting now (1)
1 drug-interventional idiopathic hypersomnia trial recruiting now, of 2 registered interventional trials. Browse all on ClinicalTrials.gov →
ALKS 2680, Placebo
Frequently asked
- How many drugs are in development for idiopathic hypersomnia?
- 2 compounds from 1 company are in active clinical development for idiopathic hypersomnia, including 1 at Phase 3 or beyond.
- Which idiopathic hypersomnia drugs are in Phase 3?
- Phase 3 (or later) programs for idiopathic hypersomnia include LUMRYZ (sodium oxybate extended-release).
- What are the next idiopathic hypersomnia trial readouts?
- Upcoming catalysts include Alixorexton (2H 2026).
- How many clinical trials are recruiting for idiopathic hypersomnia?
- 1 drug-interventional idiopathic hypersomnia trial is currently recruiting participants, out of 2 registered interventional trials.